check_circleStudy Completed

Solid tumors harboring NTRK fusion

Bayer Identifier:

21002

ClinicalTrials.gov Identifier:

NCT03206931

EudraCT Number:

Not Available

EU CT Number:

Not Available
Expanded access to provide selitrectinib for the treatment of cancers with a NTRK gene fusion

Trial purpose

Selitrectinib expanded access is for minor and adult patients with cancer having a change in a particular gene (NTRK1, NTRK2, or NTRK3 gene fusion). The patients are ineligible for an ongoing selitrectinib clinical trial or have other considerations that prevent access to selitrectinib through an existing clinical trial. Expanded access is intended to treat individual patients with different types of cancers with a NTRK gene fusion, including blood cancers, who have previously received tropomyosin receptor kinase (TRK) inhibitor therapy.

Key Participants Requirements

Sex

All

Age

1 - N/A
  • - Diagnosis of cancer with a NTRK1, NTRK2, and NTRK3 gene fusion
    - Previous treatment with a kinase inhibitor with known activity on TRK inhibition
    - Unable to participate in an ongoing selitrectinib clinical trial
    - Medically suitable for treatment with selitrectinib
  • - Currently enrolled in an ongoing clinical study with a TRK inhibitor

Trial summary

Enrollment Goal
N/A
Trial Dates
null - Today
Phase
N/A
Could I Receive a placebo
No
Products
selitrectinib (LOXO-195, BAY2731954)
Accepts Healthy Volunteer
N/A

Trial design

Expanded access to provide selitrectinib (BAY2731954) for the treatment of cancers with a NTRK gene fusion.
Trial Type
Expanded Access
Intervention Type
Drug
Trial Purpose
Treatment
Allocation
N/A
Blinding
N/A
Assignment
N/A
Trial Arms
N/A